Increased epithelial permeability in pulmonary fibrosis in relation to disease progression

Epithelial injury contributes to pathogenesis in idiopathic pulmonary fibrosis (IPF) but its role in the interstitial lung disease (ILD) of systemic sclerosis (SSc) is uncertain. We quantified the prognostic significance of inhaled technetium-99m (99mTc)-labelled diethylene triamine pentacetate (DTPA) pulmonary clearance, a marker of the extent of epithelial injury, in both diseases. Baseline 99mTc-DTPA pulmonary clearance was evaluated retrospectively in patients with SSc-ILD (n = 168) and IPF (n = 97) against mortality and disease progression. In SSc-ILD, the rapidity of total clearance (hazard ratio (HR) 1.02, 95% CI 1.01–1.03; p = 0.001) and the presence of abnormally rapid clearance (HR 2.10; 95% CI 1.25–3.53; p = 0.005) predicted a shorter time to forced vital capcity (FVC) decline, independent of disease severity. These associations were robust in both mild and severe disease. By contrast, in IPF, delayed clearance of the slow component, an expected consequence of honeycomb change, was an independent predictor of a shorter time to FVC decline (HR 1.01, 95% CI 1.00–1.02; p<0.01). Epithelial injury should be incorporated in pathogenetic models in SSc-ILD. By contrast, outcome is not linked to the overall extent of epithelial injury in IPF, apart from abnormalities ascribable to honeycombing, suggesting that core pathogenetic events may be more spatially focal in that disease.

[1]  B. Kahaleh.  The microvascular endothelium in scleroderma. , 2008, Rheumatology.

[2]  M. Fujimoto,et al.  Longitudinal analysis of serum KL-6 levels in patients with systemic sclerosis: association with the activity of pulmonary fibrosis. , 2003, Clinical and experimental rheumatology.

[3]  David A. Lynch,et al.  Idiopathic pulmonary fibrosis: Diagnosis and treatment: International Consensus Statement , 2000 .

[4]  B. Corrin,et al.  Structural features of interstitial lung disease in systemic sclerosis. , 1991, The American review of respiratory disease.

[5]  A. Nicholson,et al.  The relationship between individual histologic features and disease progression in idiopathic pulmonary fibrosis. , 2002, American journal of respiratory and critical care medicine.

[6]  D. Hansell,et al.  Clearance of inhaled 99mTc-DTPA predicts the clinical course of fibrosing alveolitis. , 1993, The European respiratory journal.

[7]  B. Giraudeau,et al.  Decrease in DL,CO in systemic sclerosis correlates with acceleration of DTPA clearance. , 1999, The European respiratory journal.

[8]  J. Jones.  The anaesthetist and respiratory dysfunction. , 1982, British journal of anaesthesia.

[9]  M. Selman,et al.  Platelet-derived growth factor in idiopathic pulmonary fibrosis. , 1990, The Journal of clinical investigation.

[10]  P. McLaughlin,et al.  Expression of tumour necrosis factor‐α in cryptogenic fibrosing alveolitis , 1993, Histopathology.

[11]  G. Raghu,et al.  A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis. , 2004, The New England journal of medicine.

[12]  A. Desmoulière,et al.  Cytoskeletal protein modulation in pulmonary alveolar myofibroblasts during idiopathic pulmonary fibrosis. Possible role of transforming growth factor beta and tumor necrosis factor alpha. , 1995, American journal of respiratory and critical care medicine.

[13]  D. Hansell,et al.  Interstitial lung disease in systemic sclerosis: a simple staging system. , 2008, American journal of respiratory and critical care medicine.

[14]  Charlie Strange,et al.  Cyclophosphamide versus placebo in scleroderma lung disease. , 2006, The New England journal of medicine.

[15]  R. D. du Bois,et al.  Fibroblast-specific perturbation of transforming growth factor beta signaling provides insight into potential pathogenic mechanisms of scleroderma-associated lung fibrosis: exaggerated response to alveolar epithelial injury in a novel mouse model. , 2008, Arthritis and rheumatism.

[16]  A. Pardo,et al.  Idiopathic Pulmonary Fibrosis: Prevailing and Evolving Hypotheses about Its Pathogenesis and Implications for Therapy , 2001, Annals of Internal Medicine.

[17]  J. Egan,et al.  Pulmonary 99mTc-DTPA aerosol clearance and survival in usual interstitial pneumonia (UIP) , 2001, Thorax.

[18]  K. Perisinakis,et al.  Clearance of technetium-99m-DTPA and HRCT findings in the evaluation of patients with Idiopathic Pulmonary Fibrosis , 2006, BMC pulmonary medicine.

[19]  B. Willis,et al.  Epithelial origin of myofibroblasts during fibrosis in the lung. , 2006, Proceedings of the American Thoracic Society.

[20]  G. Coates,et al.  Measurement of pulmonary epithelial permeability with 99mTc-DTPA aerosol. , 1986, Seminars in nuclear medicine.

[21]  American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). , 2000, American journal of respiratory and critical care medicine.

[22]  M.,et al.  Clearance of technetium-99 m-DTPA and HRCT findings in the evaluation of patients with Idiopathic Pulmonary Fibrosis , 2005 .

[23]  H. Ihn,et al.  Serum levels of KL-6 as a useful marker for evaluating pulmonary fibrosis in patients with systemic sclerosis. , 2000, The Journal of rheumatology.

[24]  J. Jones,et al.  The physiology of leaky lungs. , 1982, British journal of anaesthesia.

[25]  P. McLaughlin,et al.  Expression of tumour necrosis factor-alpha in cryptogenic fibrosing alveolitis. , 1993, Histopathology.

[26]  M. Selman,et al.  Role of epithelial cells in idiopathic pulmonary fibrosis: from innocent targets to serial killers. , 2006, Proceedings of the American Thoracic Society.

[27]  A. Nicholson,et al.  Fibrotic idiopathic interstitial pneumonia: the prognostic value of longitudinal functional trends. , 2003, American journal of respiratory and critical care medicine.

[28]  A. Nicholson,et al.  Idiopathic pulmonary fibrosis: a composite physiologic index derived from disease extent observed by computed tomography. , 2003, American journal of respiratory and critical care medicine.

[29]  W. Thurlbeck,et al.  Idiopathic pulmonary fibrosis: relationship between histopathologic features and mortality. , 2001, American journal of respiratory and critical care medicine.

[30]  A. Nicholson,et al.  Idiopathic pulmonary fibrosis: outcome in relation to smoking status. , 2008, American journal of respiratory and critical care medicine.

[31]  N. Strickland,et al.  Cause of regional ventilation-perfusion mismatching in patients with idiopathic pulmonary fibrosis: a combined CT and scintigraphic study. , 1993, AJR. American journal of roentgenology.

[32]  Arnold Simanowitz,et al.  international consensus statement , 2000 .

[33]  A. Greenberg,et al.  The role of TGF-beta in pulmonary fibrosis. , 2007, Ciba Foundation symposium.

[34]  B. Corrin,et al.  Pulmonary involvement in systemic sclerosis: the detection of early changes by thin section CT scan, bronchoalveolar lavage and 99mTc-DTPA clearance. , 1989, Respiratory medicine.

[35]  J. Jones,et al.  Solute permeability of the alveolar capillary barrier. , 1987, Thorax.